Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2019

Open Access 01-12-2019 | Human Immunodeficiency Virus | Research article

Prevalence of CCR5delta32 in Northeastern Iran

Authors: Amir Tajbakhsh, Mostafa Fazeli, Mehdi Rezaee, Faezeh Ghasemi, Mastoureh Momen Heravi, Aida Gholoobi, Zahra Meshkat

Published in: BMC Medical Genetics | Issue 1/2019

Login to get access

Abstract

Background

A 32-base pair deletion (∆32) in the open reading frame (ORF) of C-C motif chemokine receptor 5 (CCR5) seems to be a protective variant against immune system diseases, especially human immunodeficiency virus type 1 (HIV-1). We aimed to assess the frequency of CCR5∆32 in the healthy Iranian population.

Methods

In this study, 400 normal samples from Khorasan, northeastern Iran, were randomly selected. The frequency of CCR5∆32 carriers was investigated using PCR analysis. Allele prevalence and the fit to the Hardy-Weinberg equilibrium were analyzed.

Results

The prevalence of CCR5∆32 in the northeastern population of Iran was 0.016. Four hundred samples were studied, among which one with CCR5∆32/∆32 and 11 with CCR5Wild/∆32 genotype were detected.

Conclusion

This study was the first investigation for an assessment of the prevalence of CCR5∆32 in northeastern Iran. The low prevalence of CCR5∆32 allele in the Iranian population may result in the increased susceptibility to HIV-1. In addition, this prevalence is the same as that of reported in East Asia, while is lower than that in the Europeans.
Literature
1.
Taylor MFJ, Shen Y, Kreitman ME. A population genetic test of selection at the molecular-level. Science. 1995;270(5241):1497–9.PubMedCrossRef
2.
Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP. HIV-1 entry into CD4 sup+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):673.CrossRef
3.
Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367–77.PubMedCrossRef
4.
Ungvári I, Tölgyesi G, Semsei ÁF, Nagy A, Radosits K, Keszei M, Kozma GT, Falus A, Szalai C. CCR5Δ32 mutation, mycoplasma pneumoniae infection, and asthma. J Allergy Clin Immunol. 2007;119(6):1545–7.PubMedCrossRef
5.
Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med. 1997;3(3):338–40.PubMedCrossRef
6.
Bouhlal H, Latry V, Requena M, Aubry S, Kaveri SV, Kazatchkine MD, Belec L, Hocini H. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol. 2005;174(11):7202–9.PubMedCrossRef
7.
Oh D-Y, Jessen H, Kücherer C, Neumann K, Oh N, Poggensee G, Bartmeyer B, Jessen A, Pruss A, Schumann RR. CCR5Δ32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Δ32 homozygous individual. PLoS One. 2008;3(7):e2747.PubMedPubMedCentralCrossRef
8.
Agrawal L, Lu X, Qingwen J, VanHorn-Ali Z, Nicolescu IV, McDermott DH, Murphy PM, Alkhatib G. Role for CCR5Δ32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells. J Virol. 2004;78(5):2277–87.PubMedPubMedCentralCrossRef
9.
Sandford AJ, Zhu S, Bai TR, FitzGerald JM, Paré PD. The role of the CC chemokine receptor-5 Δ32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol. 2001;108(1):69–73.PubMedCrossRef
10.
Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185(9):1681–91.PubMedPubMedCentralCrossRef
11.
Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, Schneider T, Hofmann J, Kucherer C, Blau O, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–8.PubMedCrossRef
12.
Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SM, Heidari-Bakavoli AR, Safarian M, Mokhber N, Nematy M, Saber H, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60(5):561–72.PubMedCrossRef
13.
Karakaya G, YILDIRAN FAB, ARICA ŞÇ. Investigation of the frequency of the mutant CCR5-Δ32 allele related to HIV resistance in Turkey. Turk J Med Sci. 2013;43(6):886–90.CrossRef
14.
15.
16.
Nei M, Roychoudhury AK. Evolutionary relationships of human populations on a global scale. Mol Biol Evol. 1993;10(5):927–43.PubMed
17.
Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Δ32 HIV-resistance allele. Proc Natl Acad Sci U S A. 2003;100(25):15276–9.PubMedPubMedCentralCrossRef
18.
Rahimi H, Farajollahi MM, Hosseini A. Distribution of the mutated delta 32 allele of CCR5 co-receptor gene in Iranian population. Med J Islam Repub Iran. 2014;28:140.PubMedPubMedCentral
19.
Kortlandt F. The spread of the indo-Europeans. JIES. 1990;18:131–40.
20.
Lucotte G. Distribution of the CCR5 gene 32-basepair deletion in West Europe. A hypothesis about the possible dispersion of the mutation by the Vikings in historical times. Hum Immunol. 2001;62(9):933–6.PubMedCrossRef
21.
Lucotte G, Dieterlen F. More about the Viking hypothesis of origin of the Δ32 mutation in the CCR5 gene conferring resistance to HIV-1 infection. Infect Genet Evol. 2003;3(4):293–5.PubMedCrossRef
22.
Abousaidi H, Vazirinejad R, Arababadi MK, Rafatpanah H, Pourfathollah AA, Derakhshan R, Daneshmandi S, Hassanshahi G. Lack of association between chemokine receptor 5 (CCR5) d32 mutation and pathogenesis of asthma in Iranian patients. South Med J. 2011;104(6):422–5.PubMedCrossRef
23.
Arababadi MK, Hassanshahi G, Azin H, Salehabad VA, Araste M, Pourali R, Nekhei Z. No association between CCR5-Δ32 mutation and multiple sclerosis in patients of southeastern Iran. Lab Medicine. 2010;41(1):31–3.CrossRef
24.
Shahbazi M, Ebadi H, Fathi D, Roshandel D, Mahamadhoseeni M, Rashidbaghan A, Mahammadi N, Mahammadi MR, Zamani M. CCR5-Delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol. 2009;29(8):1205–9.PubMedCrossRef
25.
Omrani D. Frequency of CCR5? 32 variant in north-west of Iran. J Sci I R Iran. 2009;20(2):105–10.
26.
Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett. 2005;96(2):277–81.PubMedCrossRef
27.
Heydarifard Z, Tabarraei A, Moradi A. Polymorphisms in CCR5Δ32 and Risk of HIV-1 Infection in the Southeast of Caspian Sea, Iran. Dis Markers. 2017;2017:5.CrossRef
28.
Bineshian F, Hosseini A, Sharifi Z, Aghaie A. A study on the association between CCRΔ32 mutation and HCV infection in Iranian patients. Avicenna J Med Biotechnol. 2018;10(4):261–4.PubMedPubMedCentral
29.
Abdolmohammadi R, Shahbazi Azar S, Khosravi A, Shahbazi M. CCR5 polymorphism as a protective factor for hepatocellular carcinoma in hepatitis B virus-infected Iranian patients. Asian Pac J Cancer Prev. 2016;17(10):4643–6.PubMedPubMedCentral
30.
Amirshahi P, Sunderland E, Farhud D, Daneshmand P, Papiha S. Population genetics of the peoples of Iran I. Genetic polymorphisms of blood groups, serum proteins and red cell enzymes. Int J Anthropol. 1992;7:1–10.CrossRef
31.
Derenko M, Malyarchuk B, Bahmanimehr A, Denisova G, Perkova M, Farjadian S, Yepiskoposyan L. Complete mitochondrial DNA diversity in Iranians. PLoS One. 2013;8(11):e80673.PubMedPubMedCentralCrossRef
32.
Mehrjoo Z, Fattahi Z, Beheshtian M, Mohseni M, Poustchi H, Ardalani F, Jalalvand K, Arzhangi S, Mohammadi Z, Khoshbakht S, et al. Distinct genetic variation and heterogeneity of the Iranian population. PLoS Genet. 2019;15(9):e1008385.PubMedPubMedCentralCrossRef
33.
Farjadian S, Ghaderi A. Iranian Lurs genetic diversity: an anthropological view based on HLA class II profiles. Iran J Immunol. 2006;3(3):106–13.PubMed
34.
Ongadi B, Obiero G, Lihana R, Kiiru J. Distribution of genetic polymorphism in the CCR5 among Caucasians, Asians and Africans: a systematic review and meta-analysis. Open J Genet. 2018;08:54–66.CrossRef
35.
Hutter G, Bluthgen C, Elvers-Hornung S, Kluter H, Bugert P. Distribution of the CCR5-delta32 deletion in Southwest Germany. Anthropol Anz. 2015;72(3):303–9.PubMedCrossRef
36.
Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997;16(1):100–3.PubMedCrossRef
37.
Silva-Carvalho WH, de Moura RR, Coelho AV, Crovella S, Guimaraes RL. Frequency of the CCR5-delta32 allele in Brazilian populations: a systematic literature review and meta-analysis. Infect Genet Evol. 2016;43:101–7.PubMedCrossRef
38.
Husain S, Goila R, Shahi S, Banerjea A. First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 co-receptor-CCR5 gene. Gene. 1998;207(2):141–7.PubMedCrossRef
39.
Jawdat D, Alarifi M, Al-Turki A, Alalwan A, Al-Amro F, Atallah N, Muallimi MA, Al-Balwi M, Hajeer A. 82-p: the prevalence of CCR5 delta 32 mutation in Saudi Arabia. Hum Immunol. 2013;74:108.CrossRef
40.
Balci A, Yegin Z, Koc H. Prevalence of HIV/AIDS protective alleles (CCR5-Δ32, CCR2-64I, and SDF1-3’A) in Turkish population. Res J Biol. 2017;5(2):36-42.
41.
Solloch UV, Lang K, Lange V, Böhme I, Schmidt AH, Sauter J. Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers. Hum Immunol. 2017;78(11):710–7.PubMedCrossRef
42.
43.
Sharifi H, Mirzazadeh A, Shokoohi M, Karamouzian M, Khajehkazemi R, Navadeh S, Fahimfar N, Danesh A, Osooli M, McFarland W, et al. Estimation of HIV incidence and its trend in three key populations in Iran. PLoS One. 2018;13(11):e0207681.PubMedPubMedCentralCrossRef
44.
Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection prevalence in Iran--a systematic review and meta-analysis. PLoS One. 2016;11(3):e0151946.PubMedPubMedCentralCrossRef
45.
Haghdoost A, Mostafavi E, Mirzazadeh A, Sajadi L, Navadeh S, Feizzadeh A, Fahimfar N, Kamali K, Namdari H, Sedaghat A. Modelling of HIV/AIDS in Iran up to 2014. J AIDS HIV Res. 2011;3:231–9.CrossRef
46.
Moradi G, Piroozi B, Alinia C, Akbarpour S, Gouya M, Saadi S, Mohamadi A, Kazaerooni P. Incidence, mortality, and burden of HIV/AIDS and its geographical distribution in Iran during 2008-2016. Iran J Public Health. 2019;48:1–9.
47.
Miri R, Ahmadi Ghezeldasht S, Mosavat A, Hedayati-Moghaddam MR. No evidence of HIV infection among the general population of Mashhad, Northeast of Iran. Jundishapur J Microbiol. 2017;10(3):e43655.
48.
Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfus Med. 2007;17(6):425–33.PubMedCrossRef
49.
Pilotti E, Bianchi MV, De Maria A, Bozzano F, Romanelli MG, Bertazzoni U, Casoli C. HTLV-1/−2 and HIV-1 co-infections: retroviral interference on host immune status. Front Microbiol. 2013;4:372.PubMedPubMedCentralCrossRef
50.
Townson JR, Barcellos LF, Nibbs RJ. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol. 2002;32(10):3016–26.PubMedCrossRef
51.
Oo Z, Barrios CS, Castillo L, Beilke MA. High levels of CC-chemokine expression and downregulated levels of CCR5 during HIV-1/HTLV-1 and HIV-1/HTLV-2 coinfections. J Med Virol. 2015;87(5):790–7.PubMedCrossRef
52.
Pilotti E, Elviri L, Vicenzi E, Bertazzoni U, Re MC, Allibardi S, Poli G, Casoli C. Postgenomic up-regulation of CCL3L1 expression in HTLV-2–infected persons curtails HIV-1 replication. Blood. 2006;109(5):1850–6.PubMedCrossRef
53.
Rahimzadegan M, Abedi F, Rezaei SA, Ghadimi R. HTLV-1: ancient virus, new challenges. Rev Clin Med. 2014;1(3):141–8.
54.
55.
Beilke MA, Theall KP, O'Brien M, Clayton JL, Benjamin SM, Winsor EL, Kissinger PJ. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis. 2004;39(2):256–63.PubMedCrossRef
56.
Turci M, Pilotti E, Ronzi P, Magnani G, Boschini A, Parisi SG, Zipeto D, Lisa A, Casoli C, Bertazzoni U. Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr (1999). 2006;41(1):100–6.CrossRef
57.
Brites C, Alencar R, Gusmao R, Pedroso C, Netto EM, Pedral-Sampaio D, Badaro R. Co-infection with HTLV-1 is associated with a shorter survival time for HIV-1-infected patients in Bahia, Brazil. Aids. 2001;15(15):2053–5.PubMedCrossRef
58.
59.
Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-1 in Neyshabour, northeast of Iran. Iran Red Crescent Med J. 2011;13(6):424–7.PubMedPubMedCentral
60.
Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005;24(39):6058–68.PubMedCrossRef
61.
Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, Sohgandi L, Azarpazhooh MR, Rezaee SA, Farid R, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol. 2011;52(3):172–6.PubMedCrossRef
62.
Rahimi H, Rezaee SA, Valizade N, Vakili R, Rafatpanah H. Assessment of HTLV-I proviral load, HIV viral load and CD4 T cell count in infected subjects; with an emphasis on viral replication in co-infection. Iran J Basic Med Sci. 2014;17(1):49–54.PubMedPubMedCentral
63.
Kalavi K, Moradi A, Tabarraei A. Population-based Seroprevalence of HTLV-I infection in Golestan Province, south east of Caspian Sea, Iran. Iran J Basic Med Sci. 2013;16(3):225–8.PubMedPubMedCentral
64.
Rafatpanah H, Fathimoghadam F, Shahabi M, Eftekharzadeh I, Hedayati-Moghaddam M, Valizadeh N, Tadayon M, Shamsian SA, Bidkhori H, Miri R, et al. No evidence of HTLV-II infection among Immonoblot indeterminate samples using nested PCR in Mashhad, northeast of Iran. Iran J Basic Med Sci. 2013;16(3):229–34.PubMedPubMedCentral
65.
Weiss SH, Goedert JJ, Gartner S, Popovic M, Waters D, Markham P, di Marzo VF, Gail MH, Barkley WE, Gibbons J, et al. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science (New York, NY). 1988;239(4835):68–71.CrossRef
66.
Soria A, Alteri C, Scarlatti G, Bertoli A, Tolazzi M, Balestra E, Bellocchi MC, Continenza F, Carioti L, Biasin M, et al. Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report. Clin Infect Dis. 2017;64(6):810–3.PubMed
67.
Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, Chang JC, Bao G, Muench MO, Yu J, et al. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A. 2014;111(26):9591–6.PubMedPubMedCentralCrossRef
68.
Liu Z, Chen S, Jin X, Wang Q, Yang K, Li C, Xiao Q, Hou P, Liu S, Wu S, et al. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4(+) T cells from HIV-1 infection. Cell Biosci. 2017;7:47.PubMedPubMedCentralCrossRef
69.
Choi JG, Dang Y, Abraham S, Ma H, Zhang J, Guo H, Cai Y, Mikkelsen JG, Wu H, Shankar P, et al. Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. 2016;23(7):627–33.PubMedCrossRef
70.
Berro R, Klasse PJ, Moore JP, Sanders RW. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc. Virology. 2012;427(2):158–65.PubMedCrossRef
71.
Xiao Q, Chen S, Wang Q, Liu Z, Liu S, Deng H, Hou W, Wu D, Xiong Y, Li J, et al. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4+ T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4+ T cell enrichment in humanized mice. Retrovirology. 2019;16(1):15.PubMedPubMedCentralCrossRef
72.
73.
Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao L-F, Tran C-A, Torres-Coronado M, Gardner A, Gonzalez N. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther. 2013;21(6):1259–69.PubMedPubMedCentralCrossRef
74.
Berro R, Yasmeen A, Abrol R, Trzaskowski B, Abi-Habib S, Grunbeck A, Lascano D, Goddard WA, Klasse PJ, Sakmar TP, et al. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants. J Virol. 2013;87(12):6569–81.PubMedPubMedCentralCrossRef
75.
Asin-Milan O, Sylla M, El-Far M, Belanger-Jasmin G, Blackburn J, Chamberland A, Tremblay CL. Synergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors. Antimicrob Agents Chemother. 2014;58(12):7565–9.PubMedPubMedCentralCrossRef
76.
Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother. 2006;57(4):619–27.PubMedCrossRef
77.
Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, et al. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother. 2012;56(5):2251–8.PubMedPubMedCentralCrossRef
78.
Zhou J, Satheesan S, Li H, Weinberg MS, Morris KV, Burnett JC, Rossi JJ. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chem Biol. 2015;22(3):379–90.PubMedPubMedCentralCrossRef
Metadata
Title
Prevalence of CCR5delta32 in Northeastern Iran
Authors
Amir Tajbakhsh
Mostafa Fazeli
Mehdi Rezaee
Faezeh Ghasemi
Mastoureh Momen Heravi
Aida Gholoobi
Zahra Meshkat
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2019
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-019-0913-9

Other articles of this Issue 1/2019

BMC Medical Genetics 1/2019 Go to the issue

Research article

Genetic polymorphism in DGCR8 is associated with late onset of preeclampsia

Case report

Isolated hypoaldosteronism as first sign of X-linked adrenal hypoplasia congenita caused by a novel mutation in NR0B1/DAX-1 gene: a case report

Case report

A novel mutation in SEPN1 causing rigid spine muscular dystrophy 1: a Case report

Research article

Effect of prematurity on genome wide methylation in the placenta

Research article

A novel mutation in the OAR domain of PITX3 associated with congenital posterior subcapsular cataract

Research article

The prevalence of CGG repeat expansion mutation in FMR1 gene in the northern Chinese women of reproductive age